Improvement in Signs and Symptoms of Active Ankylosing Spondylitis Following Treatment with Anti-Interleukin (IL)-17A Monoclonal Antibody Secukinumab Are Paralleled by Reductions in Acute Phase Markers and Inflammatory Markers S100A8 and A9 (Calgranulin A and B)

Author(s):
Baeten, D.L.; Bek, S.; Wei, J.W.; Brachat, A.; Sieper, J.; Emery, P.; Braun, J.; Heijde, D. van der; McInnes, I.B.; Laar, J.M. van; Landewe, R.; Wordsworth, P.; Wollenhaupt, J.; Kellner, H.; Paramarta, J.E.; Bertolino, A.; Wright, A.; Wolfgang, H.
Published
2012
Publication type
Article / Letter to editor
Date issued
2012-10-31
Language
English
Is part of
Arthritis and Rheumatism (2012), Vol. 64, no. 10, p. S942-S942
hdl
1887/109058